Molecular imaging as a de-risking tool: coming into focus?

被引：6
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2013年 / 12卷 / 04期
关键词：
D O I：
10.1038/nrd3993
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Molecular imaging is already engrained in early-stage trials for central nervous system disorders, but used infrequently in other therapeutic areas. What will it take to make it standard practice across the pipeline?
引用
收藏
页码：251 / 252
页数：2
相关论文
共 50 条
  • [1] Molecular imaging as a de-risking tool: coming into focus?
    Asher Mullard
    [J]. Nature Reviews Drug Discovery, 2013, 12 : 251 - 252
  • [2] De-risking primary prevention: role of imaging
    Shafter, Ahmed M.
    Shaikh, Kashif
    Johanis, Amit
    Budoff, Matthew J.
    [J]. THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2021, 15
  • [3] De-risking safety
    Lautier, Samantha
    [J]. COMPUTING AND CONTROL ENGINEERING, 2006, 17 (03): : 38 - 41
  • [4] De-risking HIV
    Oirere, Shem
    [J]. CHEMISTRY & INDUSTRY, 2017, 81 (04) : 39 - 39
  • [5] DE-RISKING BUSINESS
    Jarvis, Lisa M.
    [J]. CHEMICAL & ENGINEERING NEWS, 2011, 89 (28) : 23 - 24
  • [6] Developability assessment as an early de-risking tool for biopharmaceutical development
    Zurdo, Jesus
    [J]. PHARMACEUTICAL BIOPROCESSING, 2013, 1 (01) : 29 - 50
  • [7] De-Risking Clinical Development
    Greene, Douglas A.
    [J]. GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2012, 32 (03): : 38 - 39
  • [8] De-risking regional geopolitics
    Evans, Gareth
    [J]. OXFORD REVIEW OF ECONOMIC POLICY, 2024, 40 (02) : 439 - 441
  • [9] De-risking defined benefit plans
    Lin, Yijia
    MacMinn, Richard D.
    Tian, Ruilin
    [J]. INSURANCE MATHEMATICS & ECONOMICS, 2015, 63 : 52 - 65
  • [10] Regulation and De-Risking: Theoretical and Empirical Insights
    Haar, Lawrence
    Gregoriou, Andros
    [J]. RISKS, 2023, 11 (06)
12345